Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $11.26M fell 27.2% year over year, ahead of the -28.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 36.1% from the prior quarter. Over 3 fiscal years it compounded at -18.7% a year.

Context

  • Operating expenses amounted to 71.2% of revenue in FY2025.
  • Operating expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -27.2% holds above the trailing-twelve-month pace of -28.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.26M-36.1% QoQ
Last fiscal yearDec 2025
$49.81M-36.8% YoY
LTMMar 2026
$53.18M-28.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.2%——
1 year-36.8%——
3-year CAGR-18.7%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
49.81M USD
Year-over-year change
-36.8%
4-year CAGR
-20.8%

Operating Expenses vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.1% is the lowest of 11, against a peer median of +27.7%.
  • Over three fiscal years its annual growth of -18.7% compares with a peer median of +9.6%.
BDTX Competitors
Operating Expenses for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$140.97M USD+26.8%+7.2%1258.3%
IVAInventiva S.A.FY2025€137.37M EUR+28.7%+22.8%3064.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$128.39M USD-22.9%-11.4%185.5%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$100.3M USD+45.7%+21.8%689.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$87.05M USD-28.0%-7.0%308.4%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$86.18M USD-19.9%-10.1%38304.0%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$74.72M USD+140.4%+76.7%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$68.54M USD+51.5%+11.9%116167.8%
IMRXImmuneering CorporationLTM Mar 2026$58.43M USD-8.8%+4.2%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$53.18M USD-28.1%-18.7%—
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$52.67M USD+31.8%+25.0%103.3%
Peer median (excluding BDTX) —+27.7%+9.6%974.1%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000070M
Cost of Revenue00437K0325K
Gross Profit00(437K)069.68M
Gross Margin————99.5%
Research & Development96.83M64.44M58.91M51.31M33.56M
Selling, General & Admin30.04M28.39M27.11M27.47M16.57M
Operating Expenses126.87M92.83M86.02M78.78M49.81M
Depreciation & Amortization205K508K437K343K325K
EBITDA(125.39M)(90.66M)(82.01M)(69.33M)22.69M
EBITDA Margin————32.4%
Operating Income(126.87M)(92.83M)(86.46M)(78.78M)19.87M
Operating Margin————28.4%
Interest Income3.46M2.03M1.92M2.18M4.06M
Interest Expense00000
Other Income / Expenses1.28M1.66M4.02M9.11M2.5M
Income Before Tax(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Pre-Tax Margin————32.0%
Income Tax Expense00000
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Net Margin————32.0%
EPS (Basic)(3.47)(2.52)(1.88)(1.27)0.39
EPS (Diluted)(3.47)(2.52)(1.88)(1.27)0.39
Weighted Avg Shares36.19M36.23M43.95M55.03M56.87M
Weighted Avg Shares (Diluted)36.19M36.23M43.95M55.03M57.56M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.